Excelsior Biopharma (6496) reported revenue of NT$94.8 million for Oct 2026, +32.6% year on year and +24.1% from the previous month. Revenue for Jan–Oct 2026 was NT$775.4 million (+12.3% year on year).
In Oct 2026, it ranked No. 78 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$94.8 million | +32.6% | +24.1% |
| Sep 2026 | NT$76.4 million | +7.3% | +16.1% |
| Aug 2026 | NT$65.8 million | -4.0% | -25.2% |
| Jul 2026 | NT$88 million | +30.4% | +26.8% |
| Jun 2026 | NT$69.4 million | +10.1% | -10.7% |
| May 2026 | NT$77.8 million | +6.9% | -8.9% |
| Apr 2026 | NT$85.3 million | +28.9% | +29.3% |
| Mar 2026 | NT$66 million | -16.2% | +16.9% |
| Feb 2026 | NT$56.4 million | -6.6% | -41.0% |
| Jan 2026 | NT$95.6 million | +35.1% | -23.9% |
| Dec 2025 | NT$125.6 million | +34.2% | +52.9% |
| Nov 2025 | NT$82.1 million | +12.3% | +14.9% |
| Oct 2025 | NT$71.5 million | -3.4% | +0.4% |
| Sep 2025 | NT$71.2 million | -4.6% | +3.9% |
| Aug 2025 | NT$68.5 million | -4.7% | +1.5% |
| Jul 2025 | NT$67.5 million | -5.9% | +7.0% |
| Jun 2025 | NT$63 million | -7.4% | -13.3% |
| May 2025 | NT$72.7 million | -5.0% | +9.8% |
| Apr 2025 | NT$66.2 million | -3.0% | -15.9% |
| Mar 2025 | NT$78.7 million | +40.6% | +30.3% |
| Feb 2025 | NT$60.4 million | +27.6% | -14.6% |
| Jan 2025 | NT$70.8 million | -18.5% | -24.4% |
| Dec 2024 | NT$93.6 million | +37.5% | +28.0% |
| Nov 2024 | NT$73.1 million | +1.7% | -1.2% |
| Oct 2024 | NT$74 million | +7.0% | -0.8% |
Jan–Oct 2026 cumulative: NT$775.4 million (+12.3% YoY)
Other Biotech & Medical companies
Compare with peers: Excelsior Biopharma vs PEC / Excelsior Biopharma vs Lotus Pharm / Excelsior Biopharma vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16